Lake Street downgraded Optinose (OPTN) to Hold from Buy with a price target of $9, down from $17, after Paratek Pharmaceuticals announced it will be acquiring OptiNose for up to $330M, or $14 per share. Shareholders will be granted contingent value rights worth up to $5 per share, notes the analyst, who expects no additional bids and for the deal to close in mid-2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPTN: